Psyence Biomedical announced that the registration statement pertaining to its previously announced $25M equity line of credit with White Lion Capital on Form F-1 has been declared effective by the U.S. Securities and Exchange Commission on August 28, 2024. As previously disclosed, this 24-month arrangement allows Psyence Biomed to sell up to $25M in shares to White Lion, subject to certain conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
- Psyence Biomedical Amends Note Agreements
- Psyence Biomedical files to sell 50.575M common shares for holders
- Optimi Health, Psyence Biomedical sign LOI for psilocybin drug development
- Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development